PrescribeWellness, Karmadata form data-mining deal
ALISO VIEJO, Calif. — Patient communication software maker PrescribeWellness has formed a deal with data-management firm Karmadata to send targeted patient communications to pharmacy customers, the company said Tuesday.
PrescribeWellness said the goal of the deal was to improve medication adherence and health management outcomes by using Karmadata’s data mining and analysis of patient interactions for the design and automation of personalized communications. Financial terms of the deal were not disclosed.
According to research, personal communications between pharmacists and patients can form a stronger bond between the two, thus leading to higher medication adherence.
"The obstacles to adherence are different for each patient, hence it’s important to personalize communications to fit their individual needs, and that’s where big data plays a role," PrescribeWellness CEO Al Babbington said. "The Karmadata partnership allows us to affordably provide our clients the benefits of one-to-one intervention."
Carma Laboratories brings pizzazz to lip care with Carmex Moisture Plus limited-edition designs
MILWAUKEE — Carma Laboratories on Tuesday launched Carmex Moisture Plus limited-edition designs, a slim-stick lip balm line that presents a fashion-forward exterior. The line features limited-edition designs and named personalities to match, including Chic in houndstooth, Fab in a groovy retro look, Adventurous in a leopard print and Whimsical in an art deco design.
The brand is asking consumers, “Which personality are you?”
“Lip care is an important component of a daily beauty regimen, and consumers need a product they can rely on that protects and serves as an important foundation,” stated Paul Woelbing, president of Carma Laboratories. “The goal of the new Carmex Moisture Plus line is to offer our consumers a hard-working lip balm line that represents and reflects their unique style.”
New designs will be introduced to reflect upcoming fashion trends and give consumers a unique way to flaunt their personal style. The first styles in the new line will begin to hit store shelves in late-summer 2013 at CVS, Dollar General, Walgreens, Walmart and other stores across the U.S. Suggested retail price is $2.99.
Mixing track-and-trace, compounding: Would bill unfairly burden pharmacies?
Big data finds another application and another supporter. Sort of.
The full Senate will shortly take up a new track-and-trace bill (S. 959), which would establish a national system for tracking the pedigree and movement of most pharmaceuticals, from point of manufacture and distribution to the dispensing pharmacy and the patient at the end of the supply chain. The goal: to replace the hodge-podge of different state laws with a single, nationwide track-and-trace system capable of capturing the daily flood of drug production, distribution, dispensing and utilization data and channeling it into an accessible tool by which stakeholders and regulators could secure the pharmaceutical supply chain.
All well and good, says the National Community Pharmacists Association, the biggest lobbying group for independent pharmacy. But the NCPA is unhappy with a provision of S. 959 that would significantly beef up federal oversight of pharmacy-based drug compounding in the wake of a deadly outbreak of fungal meningitis last year whose source was traced to the New England Compounding Center.
In a statement July 25, NCPA CEO Doug Hoey praised Congress’ new effort to secure the drug supply network. But Hoey also expressed “serious concerns” with the legislation. The bill, he said, “would grant FDA unrestricted authority to establish a list of ‘do not compound’ medications which, based on FDA interpretation, could impact patient access to compounded drugs.
“Community pharmacies already struggle with growing regulatory mandates, yet the legislation would also require pharmacies to notify FDA, rather than their state board of pharmacy, when compounding medications already recognized by FDA as being in short supply,” Hoey added. Hoey suggests that lawmakers split the proposed bill in two, separating the track-and-trace legislation from a new, more carefully considered effort to address the meningitis outbreak and compounding safety.
Are NCPA’s reservations justified? Do the additional FDA reporting requirements for drug compounding represent a new burden on pharmacies and a new hurdle for patient access to needed medicines? Click on the comment link to share your thoughts.